$0.14
1.82%
Nasdaq, Jul 03, 06:26 pm CET
ISIN
US89853L1044
Symbol
TTOO
Sector
Industry

T2 Biosystems, Inc. Stock price

$0.14
-0.02 12.50% 1M
-0.27 65.85% 6M
-0.28 66.67% YTD
-4.91 97.23% 1Y
-849.86 99.98% 3Y
-6,999.86 100.00% 5Y
-77,599.86 100.00% 10Y
-71,599.86 100.00% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
+0.00 1.82%
ISIN
US89853L1044
Symbol
TTOO
Sector
Industry

Key metrics

Basic
Market capitalization
$3.9m
Enterprise Value
$13.8m
Net debt
$9.8m
Cash
$2.1m
Shares outstanding
18.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.5 | 2.5
EV/Sales
1.8 | 3.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-80.6%
Return on Equity
178.6%
ROCE
655.0%
ROIC
-
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
$7.7m | $10.6m
EBITDA
$-41.3m | -
EBIT
$-41.7m | -
Net Income
$-43.0m | $-2.4b
Free Cash Flow
$-36.6m
Growth (TTM | estimate)
Revenue
-30.1% | 46.8%
EBITDA
11.6% | -
EBIT
12.0%
Net Income
13.8% | -4,761.4%
Free Cash Flow
25.7%
Margin (TTM | estimate)
Gross
-76.8%
EBITDA
-537.4% | -
EBIT
-542.6%
Net
-559.5% | -23,073.2%
Free Cash Flow
-476.6%
More
EPS
$-2.4
FCF per Share
$-2.0
Short interest
4.9%
Employees
113
Rev per Employee
$60.0k
Show more

Is T2 Biosystems, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

T2 Biosystems, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a T2 Biosystems, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a T2 Biosystems, Inc. forecast:

Hold
50%
Sell
50%

Financial data from T2 Biosystems, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.68 7.68
30% 30%
100%
- Direct Costs 14 14
18% 18%
177%
-5.89 -5.89
7% 7%
-77%
- Selling and Administrative Expenses 23 23
13% 13%
297%
- Research and Development Expense 13 13
17% 17%
163%
-41 -41
12% 12%
-537%
- Depreciation and Amortization 0.40 0.40
43% 43%
5%
EBIT (Operating Income) EBIT -42 -42
12% 12%
-542%
Net Profit -43 -43
14% 14%
-559%

In millions USD.

Don't miss a Thing! We will send you all news about T2 Biosystems, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Head office United States
CEO Craig Jalbert
Employees 113
Founded 2006
Website www.t2biosystems.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today